Cervical Cancer Screening: Will human papillomavirus testing replace cytology?

Journal of Lower Genital Tract Disease

Volumn 8, Issue 1, 2004, Pages 6-9

  Davey, Diane D ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CARCINOGENESIS; CONDYLOMA; DIAGNOSTIC ACCURACY; DNA DETERMINATION; EDITORIAL; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INTERMETHOD COMPARISON; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTION; SAFETY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS EXAMINATION; WART VIRUS;

EID: 0442326196     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/00128360-200401000-00003     Document Type: Editorial

References (22)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin 2003;53:5-26.
2. Saslow D, Runwicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
3. Myers ER, McCrory DC, Subramanian S, McCall N, Nanda K, Datta S, et al. Setting the target for a better cervical screening test: Characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol 2000;96:645-52.
4. Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC, et al. Utility of liquid-based cytology for cervical carcinoma screening: Results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer (Cancer Cytopathol) 1999;87:48-55.
5. Clavel C, Masure M, Bory J-P, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: A study of 7,392 women. Br J Cancer 2001;84:1616-23.
6. Kulasingam SI, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: Comparison, sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
7. Colgan TJ, Austin RM, Davey DC. The annual Pap test: Women's safety and public policy. Cancer (Cancer Cytopathol) 2001;93:81-5.
8. Wright TC, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489-90.
9. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical cancer screening programs. Arch Pathol Lab Med 2003;127:959-68.
10. U.S Food and Drug Administration. http://www.fda.gov/bbs/topics/NEWS/2003/NEW00890.html. Accessed July 15, 2003.
11. Bory JP, Cucherousset J, Lorenzato M, Gabriel R, Quereux C, Birembaut P, et al. Recurrent human papillomavirus infection detection with the Hybrid Capture II assay selects women with normal cervical smears at risk for development high grade cervical lesions: A longitudinal study of 3,091 women. Int J Cancer 2002;102:519-25.
12. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.
13. Seabrook JM, Hubbard RA. Achieving quality reproducible results and maintaining compliance in molecular diagnostic testing of human papillomavirus. Arch Pathol Lab Med 2003;127:978-83.
14. Stockton D, Cooper P, Lonsdale RN. Changing incidence of invasive adenocarcinoma of the uterine cervix in East Anglia. J Med Screen 1997;4:40-3.
15. Wright TC, Schiffman M, Solomon D, Cox TJ, Hatch K, Garcia F, et al. Interim guidance for the use of human papillomavirus DNA testing in combination with cytology for cervical cancer screening. Obstet Gynecol. In press.
16. Baer A, Kiviat NB, Kulasingam S, Mao C, Kuypers J, Koutsky J, Koutsky LA. Liquid-based Pap smears without a transformation zone component: Should clinicians worry? Obstet Gynecol 2002;99:1053-9.
17. Wright TC, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytological screening to detect cervical cancer. JAMA 2000;283-81-6.
18. Ducatman B, Soisson A, Reed E, Brown P, Wang W, Kramer P, et al. Adequacy of self-collected versus provider-collected liquid based Pap tests for diagnosis and HPV typing. Mod Pathol 2003;16:63A.
19. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000;96:653-6.
20. Roach N. Delivering human papillomavirus testing to the public: One patient advocate's perspective. Arch Pathol Lab Med 2003;127:995-6.
21. Montz FJ, Farber FL, Bristow RE, Cornelison T. Impact of increasing Pap test sensitivity and compliance: A modeled cost and outcomes analysis. Obstet Gynecol 2001;97:781-8.
22. Davey DD, Zarbo RJ. Conference introduction and commentary: Strategic science symposium. HPV Testing - Are you ready for a new era in cervical cancer screening? Arch Pathol Lab Med 2003;127:927-9.